Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Mar 17;15(3):969.
doi: 10.3390/pharmaceutics15030969.

Pharmacologic Management of Monogenic and Very Early Onset Inflammatory Bowel Diseases

Anne E Levine  1   2 , Dominique Mark  3 , Laila Smith  1 , Hengqi B Zheng  1   2 , David L Suskind  1   2
Affiliations
Review

Pharmacologic Management of Monogenic and Very Early Onset Inflammatory Bowel Diseases

Anne E Levine et al. Pharmaceutics. .

Abstract

Inflammatory bowel disease (IBD) is treated with a variety of immunomodulating and immunosuppressive therapies; however, for the majority of cases, these therapies are not targeted for specific disease phenotypes. Monogenic IBD with causative genetic defect is the exception and represents a disease cohort where precision therapeutics can be applied. With the advent of rapid genetic sequencing platforms, these monogenic immunodeficiencies that cause inflammatory bowel disease are increasingly being identified. This subpopulation of IBD called very early onset inflammatory bowel disease (VEO-IBD) is defined by an age of onset of less than six years of age. Twenty percent of VEO-IBDs have an identifiable monogenic defect. The culprit genes are often involved in pro-inflammatory immune pathways, which represent potential avenues for targeted pharmacologic treatments. This review will provide an overview of the current state of disease-specific targeted therapies, as well as empiric treatment for undifferentiated causes of VEO-IBD.

Keywords: management; monogenic IBD; pharmacotherapy; very early onset inflammatory bowel disease (VEO-IBD).

PubMed Disclaimer

Conflict of interest statement

Suskind and Zheng consult for Pharming LLC. No other conflict of interest exists.

References

    1. Uhlig H.H., Schwerd T., Koletzko S., Shah N., Kammermeier J., Elkadri A., Ouahed J., Wilson D.C., Travis S.P., Turner D., et al. The diagnostic approach to monogenic very early onset inflammatory bowel disease. Gastroenterology. 2014;147:990–1007.e3. doi: 10.1053/j.gastro.2014.07.023. - DOI - PMC - PubMed
    1. Worthey E.A., Mayer A.N., Syverson G.D., Helbling D., Bonacci B.B., Decker B., Serpe J.M., Dasu T., Tschannen M.R., Veith R.L., et al. Making a definitive diagnosis: Successful clinical application of whole exome sequencing in a child with intractable inflammatory bowel disease. Genet. Med. 2011;13:255–262. doi: 10.1097/GIM.0b013e3182088158. - DOI - PubMed
    1. Ouahed J., Spencer E., Kotlarz D., Shouval D.S., Kowalik M., Peng K., Field M., Grushkin-Lerner L., Pai S.Y., Bousvaros A., et al. Very Early Onset Inflammatory Bowel Disease: A Clinical Approach With a Focus on the Role of Genetics and Underlying Immune Deficiencies. Inflamm. Bowel Dis. 2020;26:820–842. doi: 10.1093/ibd/izz259. - DOI - PMC - PubMed
    1. Charbit-Henrion F., Parlato M., Hanein S., Duclaux-Loras R., Nowak J., Begue B., Rakotobe S., Bruneau J., Fourrage C., Alibeu O., et al. Diagnostic Yield of Next-generation Sequencing in Very Early-onset Inflammatory Bowel Diseases: A Multicentre Study. J. Crohns Colitis. 2018;12:1104–1112. doi: 10.1093/ecco-jcc/jjy068. - DOI - PMC - PubMed
    1. Benchimol E.I., Fortinsky K.J., Gozdyra P., Van den Heuvel M., Van Limbergen J., Griffiths A.M. Epidemiology of pediatric inflammatory bowel disease: A systematic review of international trends. Inflamm. Bowel Dis. 2011;17:423–439. doi: 10.1002/ibd.21349. - DOI - PubMed

LinkOut - more resources